• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
FBU
Click for more information
3.30% $2.93

Fletcher Building Limited Ordinary Shares - News & Media

watchlist Created with Sketch. Add to my watchlist
Industrials

Articles & Videos

Fletcher Building sells Tradelink for $170M, says plumbing division "not a natural fit"

Fletcher Building (ASX:FBU) has sold off its plumbing division, Tradelink, to Metal Manufactures Pty Ltd for a neat $170M.

12 Aug 2024 09:30 (AEST)

Fletcher Building navigates uncertain market dynamics in FY24

Fletcher Building has flagged a softening of its Materials and Distribution divisions in Australia and New Zealand.

13 May 2024 12:30 (AEST)



(20min delay)
Last
$2.93 		Change
-0.100(3.30%) 		Mkt cap ! n/a
Open High Low Value Volume
$2.95 $2.98 $2.85 $462.6K 157.6K

Buyers (Bids)

No. Vol. Price($)
0 12727 $2.92
 

Sellers (Offers)

Price($) Vol. No.
$2.94 158 0
Last trade - 06.46am 02/10/2024 (20 minute delay) ?
FBU (NZSX) Chart

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Argent hits rockchips up to 24g/t gold at Trunkey Creek, NSW Argent Minerals has unveiled rockchips containing gold grading up to 24g/t on-site its NSW-based Trunkey Creek project acreage.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Canada orders national security review over CGN's 11.26% opposition to Paladin-Fission deal Paladin has disclosed its attempted takeover of Fission Uranium Corp was blocked by a Chinese shareholder late last month.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.